JP2016519124A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519124A5 JP2016519124A5 JP2016511042A JP2016511042A JP2016519124A5 JP 2016519124 A5 JP2016519124 A5 JP 2016519124A5 JP 2016511042 A JP2016511042 A JP 2016511042A JP 2016511042 A JP2016511042 A JP 2016511042A JP 2016519124 A5 JP2016519124 A5 JP 2016519124A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- concentration
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361816899P | 2013-04-29 | 2013-04-29 | |
| US61/816,899 | 2013-04-29 | ||
| EP14305160.5 | 2014-02-05 | ||
| EP14305160 | 2014-02-05 | ||
| PCT/EP2014/058733 WO2014177568A1 (en) | 2013-04-29 | 2014-04-29 | Anti-il-4/anti-il-13 bispecific antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019004836A Division JP2019070025A (ja) | 2013-04-29 | 2019-01-16 | 抗ｉｌ−４／抗ｉｌ−１３二特異的抗体製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519124A JP2016519124A (ja) | 2016-06-30 |
| JP2016519124A5 true JP2016519124A5 (enExample) | 2017-06-22 |
| JP6470261B2 JP6470261B2 (ja) | 2019-02-13 |
Family
ID=50159179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016511042A Active JP6470261B2 (ja) | 2013-04-29 | 2014-04-29 | 抗ｉｌ−４／抗ｉｌ−１３二特異的抗体製剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10005835B2 (enExample) |
| EP (1) | EP2991678B1 (enExample) |
| JP (1) | JP6470261B2 (enExample) |
| KR (1) | KR102307257B1 (enExample) |
| CN (1) | CN105339004B (enExample) |
| AU (1) | AU2014261497B2 (enExample) |
| CA (1) | CA2910693C (enExample) |
| CL (1) | CL2015003193A1 (enExample) |
| IL (1) | IL242372B2 (enExample) |
| MX (1) | MX378502B (enExample) |
| MY (1) | MY178837A (enExample) |
| PH (1) | PH12015502441A1 (enExample) |
| RU (1) | RU2690850C2 (enExample) |
| SG (2) | SG11201508682RA (enExample) |
| TW (1) | TWI679019B (enExample) |
| WO (1) | WO2014177568A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| WO2012125775A1 (en) * | 2011-03-16 | 2012-09-20 | Sanofi | Uses of a dual v region antibody-like protein |
| CN105307641A (zh) | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
| TW201628647A (zh) | 2014-06-27 | 2016-08-16 | 賽諾菲公司 | 抗－ｉｌ４－ｉｌ１３雙特異性抗體 |
| KR101776879B1 (ko) | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| BR112018014123A2 (pt) * | 2016-01-12 | 2018-12-11 | Dr. Reddy's Laboratories Limited | formulação farmacêutica aquosa estável. |
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| MX2019007824A (es) * | 2016-12-28 | 2019-09-09 | Japan Chem Res | Preparacion liofilizada. |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| PL3615066T3 (pl) | 2017-04-28 | 2024-04-29 | Amgen Inc. | Formulacje ludzkich przeciwciał anty-RANKL i sposoby ich zastosowania |
| US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| US12202908B2 (en) | 2018-05-17 | 2025-01-21 | Astellas Pharma Inc. | Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand |
| WO2020053301A1 (en) * | 2018-09-11 | 2020-03-19 | Ichnos Sciences S.A. | Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents |
| WO2020072306A1 (en) * | 2018-10-01 | 2020-04-09 | Amgen Inc. | Methods for reducing aggregation of bispecific antibodies |
| MX2021004146A (es) | 2018-10-10 | 2021-06-08 | Astellas Pharma Inc | Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado. |
| KR102131519B1 (ko) * | 2018-10-30 | 2020-07-07 | 가톨릭대학교 산학협력단 | 간암 전이 진단 또는 예후 예측용 바이오마커 및 이의 용도 |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| TWI883004B (zh) * | 2019-05-24 | 2025-05-11 | 法商賽諾菲公司 | 治療全身性硬化症之方法 |
| US12553041B2 (en) | 2019-06-04 | 2026-02-17 | Cartesian Therapeutics Inc. | Formulations and doses of pegylated uricase |
| GB201911461D0 (en) * | 2019-08-09 | 2019-09-25 | Arecor Ltd | Novel composition |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CA3174988A1 (en) * | 2020-03-11 | 2021-09-16 | Selecta Biosciences, Inc. | Methods and compositions related to synthetic nanocarriers |
| FI129383B (en) | 2020-06-15 | 2022-01-31 | Faron Pharmaceuticals Oy | Stable anti-clever-1 antibody formulation |
| CN119950703B (zh) * | 2024-07-08 | 2025-10-28 | 武汉友芝友生物制药股份有限公司 | 抗体制剂 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP2005512522A (ja) | 2001-10-26 | 2005-05-12 | セントカー・インコーポレーテツド | Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用 |
| US20040023338A1 (en) | 2001-10-26 | 2004-02-05 | Heavner George A. | IL-4 mutein proteins, antibodies, compositions, methods and uses |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| WO2006042333A2 (en) | 2004-10-12 | 2006-04-20 | Xencor, Inc. | Prediction and assessment of immunogenicity |
| JP5419709B2 (ja) * | 2007-01-09 | 2014-02-19 | ワイス・エルエルシー | 抗ｉｌ−１３抗体製剤およびその使用 |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2225275A4 (en) | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
| EP2196476A1 (en) | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| WO2011017070A1 (en) * | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| KR20130031247A (ko) * | 2010-03-17 | 2013-03-28 | 애보트 리서치 비.브이. | 항―신경 성장 인자（ｎｇｆ） 항체 조성물 |
| WO2012125775A1 (en) * | 2011-03-16 | 2012-09-20 | Sanofi | Uses of a dual v region antibody-like protein |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AP2014007588A0 (en) * | 2011-09-22 | 2014-04-30 | Amgen Inc | CD27L antigen binding proteins |
| CN102961745B (zh) * | 2012-09-27 | 2015-02-18 | 苏州康聚生物科技有限公司 | 抗体组合物制剂及其应用 |
-
2014
- 2014-04-25 TW TW103114922A patent/TWI679019B/zh active
- 2014-04-29 CN CN201480037173.9A patent/CN105339004B/zh active Active
- 2014-04-29 AU AU2014261497A patent/AU2014261497B2/en active Active
- 2014-04-29 US US14/787,507 patent/US10005835B2/en active Active
- 2014-04-29 RU RU2015150149A patent/RU2690850C2/ru active
- 2014-04-29 MY MYPI2015703782A patent/MY178837A/en unknown
- 2014-04-29 KR KR1020157032914A patent/KR102307257B1/ko active Active
- 2014-04-29 EP EP14724659.9A patent/EP2991678B1/en active Active
- 2014-04-29 MX MX2015015152A patent/MX378502B/es unknown
- 2014-04-29 JP JP2016511042A patent/JP6470261B2/ja active Active
- 2014-04-29 WO PCT/EP2014/058733 patent/WO2014177568A1/en not_active Ceased
- 2014-04-29 SG SG11201508682RA patent/SG11201508682RA/en unknown
- 2014-04-29 CA CA2910693A patent/CA2910693C/en active Active
- 2014-04-29 IL IL242372A patent/IL242372B2/en unknown
- 2014-04-29 SG SG10201708746RA patent/SG10201708746RA/en unknown
-
2015
- 2015-10-22 PH PH12015502441A patent/PH12015502441A1/en unknown
- 2015-10-29 CL CL2015003193A patent/CL2015003193A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015150149A (ru) | Составы на основе биспецифических антител к il-4/il-13 | |
| TWI853077B (zh) | 新型抗ｃｄ３９抗體 | |
| WO2021244089A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| Sun et al. | Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic | |
| JP2012254092A5 (enExample) | ||
| JP2011527899A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| JP2019536806A5 (enExample) | ||
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| JP2012525829A5 (enExample) | ||
| PE20121646A1 (es) | Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica | |
| RU2019132843A (ru) | Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение | |
| FI3309176T3 (fi) | Immunoglobuliinin yksittäinen vaihteleva domeeni -vasta-aineita ox40l:ää vastaan, konstrukteja ja niiden terapeuttinen käyttö | |
| CN103396481B (zh) | 一种二型登革热病毒ns1蛋白的重链单域抗体及其制备方法和应用 | |
| JP2012518425A5 (enExample) | ||
| RU2017116847A (ru) | Антитела к pd-1 | |
| JP2016509009A5 (enExample) | ||
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| AR058955A1 (es) | Inmunglobulinas que se unen a interleuquina 13 | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2011527902A5 (enExample) | ||
| EA201190275A1 (ru) | Белок, связывающий интерлейкин-13 (il-13) | |
| AR075849A1 (es) | Moleculas de anticuerpos que tienen especificidad de union por il-13 humana |